Patents by Inventor Rajesh Kumar Thaper

Rajesh Kumar Thaper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8552197
    Abstract: The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III).
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: October 8, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130210885
    Abstract: The present invention relates to crystalline forms of L-malic acid salt of sunitinib and its preparation. The crystalline forms of the present invention are designated as Form V and Form VI of L-malic acid salt of sunitinib. Formula (I).
    Type: Application
    Filed: January 28, 2011
    Publication date: August 15, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Sudhir Singh Sanwal, Saridi Madhava Dileep Kumar, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130210865
    Abstract: The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib.
    Type: Application
    Filed: January 28, 2011
    Publication date: August 15, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad, Sachin Deorao Zade, Ajay Shankar Sinch
  • Publication number: 20130204002
    Abstract: The present invention relates to a process for the preparation of crystalline dexlansoprazole.
    Type: Application
    Filed: March 29, 2011
    Publication date: August 8, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Anu Mittal, Anmol Kumar Ray, Mahavir Singh Khanna, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130197232
    Abstract: The present invention relates to crystalline forms of dexlansoprazole designated as forms A and B, and their preparation. The present invention further relates to processes for the preparation of anhydrous dexlansoprazole and dexlansoprazole sesquihydrate using crystalline Forms A and B of dexlansoprazole.
    Type: Application
    Filed: January 28, 2011
    Publication date: August 1, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Anmol Kumar Ray, Mahavir Singh Khanna, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130197233
    Abstract: The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole.
    Type: Application
    Filed: March 29, 2011
    Publication date: August 1, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Anu Mittal, Anmol Kumar Ray, Mahavir Singh Khanna, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130123511
    Abstract: The present invention relates to a process for the direct preparation of malic acid salt of sunitinib.
    Type: Application
    Filed: February 25, 2011
    Publication date: May 16, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Sudhir Singh Sanwal, Saridi Madhava Dileep Kumar, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Patent number: 8440823
    Abstract: The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 14, 2013
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Balaguru Murugesan, Anandam Vempali, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130005777
    Abstract: The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III).
    Type: Application
    Filed: November 12, 2010
    Publication date: January 3, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20130005980
    Abstract: The present invention provides a process for the preparation of sorafenib tosylate, comprising contacting sorafenib free base with p-toluenesulphonic acid in water.
    Type: Application
    Filed: September 24, 2010
    Publication date: January 3, 2013
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120302749
    Abstract: The present invention relates to processes for the preparation of erlotinib hydrochloride Form A and erlotinib hydrochloride Form B. (I).
    Type: Application
    Filed: November 12, 2010
    Publication date: November 29, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Balaguru Murugesan, Anandam Vempali, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120283440
    Abstract: The present invention relates to crystalline forms of bosentan salts and processes for their preparation.
    Type: Application
    Filed: November 12, 2010
    Publication date: November 8, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Rakesh Singh, Anu Mittal, Gopal Singh Bisht, Mahavir Singh Khanna, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120271056
    Abstract: The present invention relates to a process for the preparation of crystalline Form I of the L-malic acid salt of sunitinib.
    Type: Application
    Filed: November 12, 2010
    Publication date: October 25, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Sudhir Singh Sanwal, Saridi Madhava Dileep Kumar, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120264789
    Abstract: The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.
    Type: Application
    Filed: September 24, 2010
    Publication date: October 18, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Jagdev Singh Jaryal, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Patent number: 8278461
    Abstract: The present invention provides a novel stable amorphous form of carvedilol dihydrogen phosphate and the process for its preparation that involves reaction of carvedilol base with ortho phosphoric acid in the presence of stabilizer in a suitable solvent or mixture of solvents followed by concentration and isolation. An alternate process for preparation of amorphous form of carvedilol dihydrogen phosphate involves addition of stabiliser to the solution of stable amorphous or crystalline carvedilol dihydrogen phosphate in a suitable solvent or mixture of solvents followed by concentration and isolation. The novel stable amorphous form of carvedilol dihydrogen phosphate is highly stable.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 2, 2012
    Assignee: Lupin Limited
    Inventors: Rajesh Kumar Thaper, Manoj Devilalji Prabhavat, Yogesh Dadaji Pawar, Pritesh R. Upadhyay
  • Publication number: 20120220783
    Abstract: The present invention relates to salts of sunitinib and their preparation.
    Type: Application
    Filed: September 16, 2010
    Publication date: August 30, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Sudhir Singh Sanwal, Saridi Madhava Dileep Kumar, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120220777
    Abstract: The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide.
    Type: Application
    Filed: September 16, 2010
    Publication date: August 30, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Saridi Madhava Dileep Kumar, Munish Kapoor, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120190849
    Abstract: The present invention provides processes for the preparation of vardenafil, its pharmaceutically acceptable salts, hydrates and intermediates.
    Type: Application
    Filed: August 9, 2010
    Publication date: July 26, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Anu Mittal, Mahavir Singh Khanna, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120184746
    Abstract: The present invention relates to a process for the preparation of lenalidomide, wherein the process comprises: reducing 3-(4-nitro-loxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione to obtain lenalidomide.
    Type: Application
    Filed: September 3, 2010
    Publication date: July 19, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Munish Kapoor, Saridi Madhava Dileep Kumar, Balaguru Murugesan, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad
  • Publication number: 20120101272
    Abstract: The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.
    Type: Application
    Filed: March 26, 2010
    Publication date: April 26, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Balaguru Murugesan, Anandam Vempali, Swargam Sathyanarayana, Rajesh Kumar Thaper, Mohan Prasad